Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP531530.RAdJcO5xpfCrWwmJRQ4U7uQ-W8hVn9G8FQxzTM5V_UEwE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP531530.RAdJcO5xpfCrWwmJRQ4U7uQ-W8hVn9G8FQxzTM5V_UEwE130_assertion type Assertion NP531530.RAdJcO5xpfCrWwmJRQ4U7uQ-W8hVn9G8FQxzTM5V_UEwE130_head.
- NP531530.RAdJcO5xpfCrWwmJRQ4U7uQ-W8hVn9G8FQxzTM5V_UEwE130_assertion description "[Evaluation of the findings for all 462 tumors as well as for node-positive and -negative subgroups revealed less favorable findings for overall survival and the disease-free period for both p53-positive tumors (for total group, overall survival, P = 0.0002, disease-free period, P = 0.02; for node-positive group, overall survival, P = 0.0004, disease-free period, P = 0.1045) and breast carcinomas with higher proportions of cell nuclei positive for MIB-1 (total, overall survival, P = 0.0026, disease-free period, P = 0.0022; node-positive, overall survival, P = 0.021, disease-free period, P = 0.0882).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP531530.RAdJcO5xpfCrWwmJRQ4U7uQ-W8hVn9G8FQxzTM5V_UEwE130_provenance.
- NP531530.RAdJcO5xpfCrWwmJRQ4U7uQ-W8hVn9G8FQxzTM5V_UEwE130_assertion evidence source_evidence_literature NP531530.RAdJcO5xpfCrWwmJRQ4U7uQ-W8hVn9G8FQxzTM5V_UEwE130_provenance.
- NP531530.RAdJcO5xpfCrWwmJRQ4U7uQ-W8hVn9G8FQxzTM5V_UEwE130_assertion SIO_000772 7705708 NP531530.RAdJcO5xpfCrWwmJRQ4U7uQ-W8hVn9G8FQxzTM5V_UEwE130_provenance.
- NP531530.RAdJcO5xpfCrWwmJRQ4U7uQ-W8hVn9G8FQxzTM5V_UEwE130_assertion wasDerivedFrom befree-20140225 NP531530.RAdJcO5xpfCrWwmJRQ4U7uQ-W8hVn9G8FQxzTM5V_UEwE130_provenance.
- NP531530.RAdJcO5xpfCrWwmJRQ4U7uQ-W8hVn9G8FQxzTM5V_UEwE130_assertion wasGeneratedBy ECO_0000203 NP531530.RAdJcO5xpfCrWwmJRQ4U7uQ-W8hVn9G8FQxzTM5V_UEwE130_provenance.